Recent Updates
Recently added Catalysts

Bexarotene

Phase 2

Sarcoma, Kaposi | Small molecule | Oncology |Ligand Pharmaceuticals Incorporated|Last Updated: May 30, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment27

FDA Designations

No designations recorded

Clinical trial landscape

Bexarotene · 3 trials · 4 indications

Phase 2 2Phase 1 1
NCT00003752Bexarotene in Treating Patients With Metastatic Breast CancerBreast Cancer
COMPLETED180 Analytics
NCT00002212A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's SarcomaSarcoma, Kaposi
COMPLETED27 Analytics
PHASE2COMPLETED
Bexarotene in Treating Patients With Metastatic Breast Cancer
Breast Cancer
NCT00003752180
Unlock trial analytics
PHASE2COMPLETED
A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma
Sarcoma, Kaposi
NCT0000221227
Unlock trial analytics

Study Endpoints

Primary Endpoints

Safety and tolerability of bexarotene in combination with ECP, assessed with NCI toxicity assessment, at each treatment visit, every 3 weeks and at final one month foll

Secondary Endpoints

Time to response of bexarotene with ECP in patients with CTCL, at month 4 (follow-up visit) patient's response by organ system involvement, with an overall assessment: complete response, partial response, no change, or progressive disease, flare.
Another secondary outcome is whether combination of instruments provides relevant information on CTCL patients' health related quality of life during therapy
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
PurposeTREATMENT

Interventions

NameTypeDescription
bexaroteneDRUG -
photopheresisDEVICE -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites30

DISEASE CHARACTERISTICS: Histologically confirmed metastatic breast cancer No CNS metastases No rapidly progressing visceral disease Previously irradiated lesions(s) may be designated as measurable indicator tumor(s) only if more than 6 months since radiotherapy, patient has no other measurable dise...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Bexarotene

What is Bexarotene used for?

Bexarotene is an investigational small molecule being studied for the treatment of cutaneous T-cell lymphoma, sarcoma, Kaposi, and breast cancer. It is being developed by Ligand Pharmaceuticals Incorporated (LGND) and is currently in Phase 2 clinical development.

Who makes Bexarotene?

Bexarotene is being developed by Ligand Pharmaceuticals Incorporated, a company traded on the stock exchange under the ticker symbol LGND. The drug is currently in Phase 2 clinical trials for oncology indications.

What phase is Bexarotene in?

Bexarotene is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed for its study in various oncology conditions.

What clinical trials is Bexarotene in?

Bexarotene has been studied in clinical trials including NCT00002212 for AIDS-related Kaposi's sarcoma, NCT00003752 for metastatic breast cancer, and NCT00306969 for cutaneous T-cell lymphoma. These trials have been completed.

Is Bexarotene the same as Targretin?

Bexarotene is also known by the brand name Targretin. In clinical trial NCT00002212, the study title refers to Targretin capsules, confirming that Targretin is an alternative name for Bexarotene.